A Phase 3 interventional study of Somatropin in Endocrine System Diseases, sponsored by Pfizer. Terminated at 2 sites in France. Open to participants aged 11 Years to 17 Years. Per ClinicalTrials.gov, last updated 2012-12-04.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This trial terminated on 10-Jun-2011 due to prolonged issues with drug accountability and data collection discrepancies. The decision to terminate was not based on any safety concerns.
322 studies on the registry are indexed under Endocrine System Diseases; 51 are open to participants now.
This study's enrollment of 30 is below the median of 69 across 221 interventional studies indexed under Endocrine System Diseases.
Browse Endocrine System Diseases studies →Pfizer is the lead sponsor of 3,337 studies on the registry; 146 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Somatropin
liquid, daily, until final height Dosage: 0,46 mg/kg/week . The maximum dose should not exceed 50 µg/Kg/day
Change From Baseline in Height Standard Deviation Score According to Chronological Age (SDS/CA) at Year 3
Height was measured using a wall mounted device (example, Harpenden stadiometer). Height SDS/CA was obtained by measuring the height, subtracting chronological age- and gender-appropriate mean height and dividing the result by standard deviation of that mean (as obtained from chronological age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.
Time frame: Baseline, Year 3
Change From Baseline in Height Standard Deviation Score According to Chronological Age (SDS/CA) at Final Height
Height was measured using a wall mounted device (example, Harpenden stadiometer). Height SDS/CA was obtained by measuring the height, subtracting chronological age- and gender-appropriate mean height and dividing the result by standard deviation of that mean (as obtained from chronological age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.
Time frame: Baseline, when final height was reached (assessed up to Year 11)
Change From Baseline in Weight Standard Deviation Score (SDS) at Final Height
Body weight was measured using a balance scale. Weight SDS was obtained by measuring the weight, subtracting age- and gender-appropriate mean weight and dividing the result by standard deviation of that mean (as obtained from age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.
Time frame: Baseline, when final height was reached (assessed up to Year 11)
Puberty Stage at Final Height
Pubertal stage (graded from I to V for breast development and pubic hair development) according to the Tanner's method was collected. A low stage (Stage I) corresponds to a pre-pubertal stage and a high stage (Stage V) to an adult stage.
Time frame: When final height was reached (assessed up to Year 11)
Bone Age
Bone age was determined by the Greulich and Pyle method using left wrist and hand X-ray.
Time frame: Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
Lean Body Mass
Lean body mass, a measurement of body composition, was assessed by Dual Energy X-ray Absorptiometry (DEXA) scan.
Time frame: Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
Annual Percent Change in Lean Body Mass at Year 1, 2 and 3
Lean body mass, a measurement of body composition, was assessed by DEXA scan. Annual percent change: (Lean body mass at current year minus lean body mass at previous year) divided by lean body mass at previous year, multiplied by 100.
Time frame: Baseline, Year 1, 2, 3
Percent Change From Baseline in Lean Body Mass at Year 3
Lean body mass, a measurement of body composition, was assessed by DEXA scan. Percent change: (Lean body mass at Year 3 minus lean body mass at baseline) divided by lean body mass at baseline, multiplied by 100.
Time frame: Baseline, Year 3
Lean Body Mass as Percentage of Total Weight
Lean body mass, a measurement of body composition, was assessed by DEXA scan.
Time frame: Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
Lean Body Mass Standard Deviation Score According to Chronological Age (SDS/CA)
Lean body mass was assessed by DEXA scan. Lean body mass SDS/CA was obtained by measuring lean body mass, subtracting the chronological age- and gender-appropriate mean lean body mass and dividing the result by standard deviation of that mean (as obtained from chronological age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.
Time frame: Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
Fat Mass
Fat mass, a measurement of body composition, was assessed by DEXA scan.
Time frame: Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
Annual Percent Change in Fat Mass at Year 1, 2 and 3
Fat mass, a measurement of body composition, was assessed by DEXA scan. Annual percent change: (Fat mass at current year minus fat mass at previous year) divided by fat mass at previous year, multiplied by 100.
Time frame: Baseline, Year 1, 2, 3
Percent Change From Baseline in Fat Mass at Year 3
Fat mass, a measurement of body composition, was assessed by DEXA scan. Percent change: (Fat mass at Year 3 minus fat mass at baseline) divided by fat mass at baseline, multiplied by 100.
Time frame: Baseline, Year 3
Fat Mass as Percentage of Total Weight
Fat mass, a measurement of body composition, was assessed by DEXA scan.
Time frame: Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
Fat Mass Standard Deviation Score According to Chronological Age (SDS/CA)
Fat mass was assessed by DEXA scan. Fat mass SDS/CA was obtained by measuring fat mass, subtracting chronological age- and gender-appropriate mean fat mass and dividing the result by standard deviation of that mean (as obtained from chronological age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.
Time frame: Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
Apparent Bone Mineral Density of Lumbar Spine (BMAD [LS])
BMAD (LS) was assessed by DEXA scan.
Time frame: Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
Apparent Bone Mineral Density Standard Deviation Score of Lumbar Spine According to Chronological Age (BMAD [LS] [SDS/CA])
BMAD (LS) was assessed by DEXA scan. BMAD (LS) (SDS/CA) was obtained by measuring the BMAD (LS), subtracting chronological age- and gender-appropriate mean BMAD (LS) and dividing the result by standard deviation of that mean (as obtained from chronological age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.
Time frame: Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
Apparent Bone Mineral Density Standard Deviation Score of Lumber Spine According to Tanner Puberty Stage (BMAD [LS] [SDS/Tanner Puberty Stage])
BMAD (LS) was assessed by DEXA scan. BMAD (LS) (SDS/Tanner Puberty Stage) was obtained by measuring BMAD (LS), subtracting Tanner puberty stage- and gender-appropriate mean BMAD (LS) and dividing the result by standard deviation of that mean (as obtained from Tanner puberty stage- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.
Time frame: Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
Bone Mineral Density of Total Body (BMD [TB])
BMD (TB) was assessed by DEXA scan.
Time frame: Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
Bone Mineral Density of Lumbar Spine (BMD [LS])
BMD (LS) was assessed by DEXA scan.
Time frame: Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
Bone Mineral Content of Total Body (BMC [TB])
DEXA scan of BMC was used to evaluate potential bone effects of treatment. BMC is an estimate of the amount of mineral (such as calcium) in the bone.
Time frame: Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
Annual Percent Change in Bone Mineral Content of Total Body (BMC [TB]) at Year 1, 2 and 3
BMC is an estimate of the amount of mineral (such as calcium) in the bone. Annual percent change: (BMC \[TB\] at current year minus BMC \[TB\] at previous year) divided by BMC \[TB\] at previous year, multiplied by 100.
Time frame: Baseline, Year 1, 2, 3
Percent Change From Baseline in Bone Mineral Content of Total Body (BMC [TB]) at Year 3
BMC is an estimate of the amount of mineral (such as calcium) in the bone. Percent change: (BMC \[TB\] at Year 3 minus BMC \[TB\] at baseline) divided by BMC \[TB\] at baseline, multiplied by 100.
Time frame: Baseline, Year 3
Bone Mineral Content Standard Deviation Score of Total Body According to Chronological Age (BMC [TB] [SDS/CA])
BMC (TB) was measured by DEXA scan. BMC (TB) (SDS/CA) was obtained by measuring BMC (TB), subtracting the chronological age- and gender-appropriate mean BMC (TB) and dividing the result by standard deviation of that mean (as obtained from chronological age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.
Time frame: Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
Bone Mineral Content Standard Deviation Score of Total Body According to Tanner Puberty Stage (BMC [TB] [SDS/Tanner Puberty Stage])
BMC (TB) was measured by DEXA scan. BMC (TB) (SDS/Tanner Puberty Stage) was obtained by measuring BMC (TB), subtracting the Tanner puberty stage- and gender-appropriate mean BMC (TB) and dividing the result by standard deviation of that mean (as obtained from Tanner puberty stage- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.
Time frame: Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
Growth Velocity (GV)
Growth velocity measures the annual rate of increase in height.
Time frame: Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
Growth Velocity Standard Deviation Score According to Chronological Age (GV [SDS/CA])
GV measures the annual rate of increase in height. GV (SDS/CA) was obtained by measuring GV, subtracting the chronological age- and gender-appropriate mean GV and dividing the result by standard deviation of that mean (as obtained from chronological age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.
Time frame: Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
Growth Velocity Standard Deviation Score According to Bone Age (GV [SDS/BA])
GV measures the annual rate of increase in height. GV (SDS/BA) was obtained by measuring GV, subtracting the bone age- and gender-appropriate mean GV and dividing the result by standard deviation of that mean (as obtained from bone age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.
Time frame: Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
Insulin-like Growth Factor-1 (IGF-1) Concentration up to Year 3
Time frame: Baseline, Year 1, 2, 3
Insulin-like Growth Factor-1 (IGF-1) Concentration After Year 3
Time frame: Year 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10; 0.5 and 1 year after somatropin discontinuation, Final Height (assessed up to Year 11)
| Milestone | Somatropin- Up To Year 3 (Juvenile Idiopathic Arthritis) | Somatropin- Up To Year 3 (Nephrotic Syndrome) | Somatropin- After Year 3 |
|---|---|---|---|
| Started | 15 | 15 | 0 |
| Completed | 15 | 11 | 0 |
| Not completed | 0 | 4 | 0 |
| Withdrew: Serious adverse event | 0 | 1 | 0 |
| Withdrew: Non compliance | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 |
| Withdrew: Other | 0 | 1 | 0 |
| Milestone | Somatropin- Up To Year 3 (Juvenile Idiopathic Arthritis) | Somatropin- Up To Year 3 (Nephrotic Syndrome) | Somatropin- After Year 3 |
|---|---|---|---|
| Started | 0 | 0 | 26 |
| Consented | 0 | 0 | 24 |
| Completed | 0 | 0 | 21 |
| Not completed | 0 | 0 | 5 |
| Withdrew: Did not consent to continue treatment | 0 | 0 | 2 |
| Withdrew: Consented, not assigned to treatment | 0 | 0 | 3 |
| Milestone | Somatropin- Up To Year 3 (Juvenile Idiopathic Arthritis) | Somatropin- Up To Year 3 (Nephrotic Syndrome) | Somatropin- After Year 3 |
|---|---|---|---|
| Started | 0 | 0 | 21 |
| Completed | 0 | 0 | 13 |
| Not completed | 0 | 0 | 8 |
| Withdrew: Lost to follow-up | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
| Withdrew: Other | 0 | 0 | 5 |
Height was measured using a wall mounted device (example, Harpenden stadiometer). Height SDS/CA was obtained by measuring the height, subtracting chronological age- and gender-appropriate mean height and dividing the result by standard deviation of that mean (as obtained from chronological age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.
| Standard Deviation Score (SDS) | Somatropin- Up To Year 3 (Juvenile Idiopathic Arthritis) | Somatropin- Up To Year 3 (Nephrotic Syndrome) |
|---|---|---|
| Baseline | -3.6 (-5.1 to -2.3) | -2.5 (-2.8 to -2.2) |
| Change at Year 3 | 0.2 (-1.5 to 1.8) | 1.1 (0.8 to 1.5) |
Height was measured using a wall mounted device (example, Harpenden stadiometer). Height SDS/CA was obtained by measuring the height, subtracting chronological age- and gender-appropriate mean height and dividing the result by standard deviation of that mean (as obtained from chronological age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.
| SDS | Somatropin- After Year 3 |
|---|---|
| Baseline (n = 21) | -2.86 (-5.61 to -1.00) |
| Change at Final Height (n = 4) | 0.71 (0.27 to 3.08) |
Body weight was measured using a balance scale. Weight SDS was obtained by measuring the weight, subtracting age- and gender-appropriate mean weight and dividing the result by standard deviation of that mean (as obtained from age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.
| SDS | Somatropin- After Year 3 |
|---|---|
| Baseline (n = 21) | -1.53 (-4.77 to 2.64) |
| Change at Final Height (n = 4) | -0.43 (-1.37 to 1.09) |
Pubertal stage (graded from I to V for breast development and pubic hair development) according to the Tanner's method was collected. A low stage (Stage I) corresponds to a pre-pubertal stage and a high stage (Stage V) to an adult stage.
| participants | Somatropin- After Year 3 |
|---|---|
| Pubic hair: Stage I (n=4) | 0 |
| Pubic hair: Stage II (n=4) | 0 |
| Pubic hair: Stage III (n=4) | 0 |
| Pubic hair: Stage IV (n=4) | 0 |
| Pubic hair: Stage V (n=4) | 4 |
| Breast development: Stage I (n=1) | 0 |
| Breast development: Stage II (n=1) | 0 |
| Breast development: Stage III (n=1) | 0 |
| Breast development: Stage IV (n=1) | 0 |
| Breast development: Stage V (n=1) | 1 |
Bone age was determined by the Greulich and Pyle method using left wrist and hand X-ray.
| years | Somatropin- Up To Year 3 (Juvenile Idiopathic Arthritis) | Somatropin- Up To Year 3 (Nephrotic Syndrome) |
|---|---|---|
| Baseline (n = 14, 15) | 8.9 (7.0 to 10.0) | 10.5 (7.0 to 13.0) |
| Year 1 (n = 14, 15) | 9.5 (7.8 to 11.5) | 11.5 (7.0 to 14.0) |
| Year 2 (n = 15, 13) | 10.0 (8.0 to 13.0) | 14.0 (10.0 to 14.5) |
| Year 3 (n = 15, 14) | 11.3 (8.8 to 14.5) | 14.0 (11.5 to 15.0) |
Lean body mass, a measurement of body composition, was assessed by Dual Energy X-ray Absorptiometry (DEXA) scan.
| kilogram (kg) | Somatropin- Up To Year 3 (Juvenile Idiopathic Arthritis) | Somatropin- Up To Year 3 (Nephrotic Syndrome) |
|---|---|---|
| Baseline (n = 15, 15) | 17.69 (14.96 to 19.96) | 23.56 (16.77 to 32.43) |
| Year 1 (n = 15, 13) | 19.77 (16.62 to 24.58) | 31.16 (20.77 to 39.10) |
| Year 2 (n = 14, 12) | 21.20 (18.79 to 25.13) | 34.14 (25.30 to 46.30) |
| Year 3 (n = 14, 11) | 23.21 (20.88 to 25.55) | 36.38 (26.49 to 42.76) |
Lean body mass, a measurement of body composition, was assessed by DEXA scan. Annual percent change: (Lean body mass at current year minus lean body mass at previous year) divided by lean body mass at previous year, multiplied by 100.
| percent change | Somatropin- Up To Year 3 (Juvenile Idiopathic Arthritis) | Somatropin- Up To Year 3 (Nephrotic Syndrome) |
|---|---|---|
| Annual Change at Year 1 (n = 15, 13) | 18.95 (10.04 to 21.83) | 22.97 (17.54 to 28.80) |
| Annual Change at Year 2 (n = 14, 11) | 7.75 (1.31 to 12.16) | 7.33 (4.76 to 18.91) |
| Annual Change at Year 3 (n = 13, 9) | 9.83 (2.67 to 13.33) | 7.90 (1.88 to 15.08) |
Lean body mass, a measurement of body composition, was assessed by DEXA scan. Percent change: (Lean body mass at Year 3 minus lean body mass at baseline) divided by lean body mass at baseline, multiplied by 100.
| percent change | Somatropin- Up To Year 3 (Juvenile Idiopathic Arthritis) | Somatropin- Up To Year 3 (Nephrotic Syndrome) |
|---|---|---|
| Percent Change From Baseline in Lean Body Mass at Year 3 | 36.82 (22.45 to 52.39) | 54.44 (43.06 to 62.30) |
Lean body mass, a measurement of body composition, was assessed by DEXA scan.
| percentage of total weight | Somatropin- Up To Year 3 (Juvenile Idiopathic Arthritis) | Somatropin- Up To Year 3 (Nephrotic Syndrome) |
|---|---|---|
| Baseline (n = 15, 15) | 70.56 (58.25 to 80.10) | 60.69 (55.29 to 69.14) |
| Year 1 (n = 15, 13) | 76.57 (64.16 to 83.89) | 65.97 (59.58 to 76.19) |
| Year 2 (n = 14, 12) | 73.32 (63.85 to 80.96) | 69.95 (59.55 to 80.07) |
| Year 3 (n = 14, 11) | 72.94 (66.79 to 78.21) | 67.24 (59.83 to 74.37) |
Lean body mass was assessed by DEXA scan. Lean body mass SDS/CA was obtained by measuring lean body mass, subtracting the chronological age- and gender-appropriate mean lean body mass and dividing the result by standard deviation of that mean (as obtained from chronological age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.
| SDS | Somatropin- Up To Year 3 (Juvenile Idiopathic Arthritis) | Somatropin- Up To Year 3 (Nephrotic Syndrome) |
|---|---|---|
| Baseline (n = 15, 15) | -1.50 (-1.81 to -0.94) | -0.90 (-1.40 to -0.54) |
| Year 1 (n = 15, 13) | -1.13 (-1.64 to -0.67) | -0.52 (-0.97 to 0.20) |
| Year 2 (n = 14, 12) | -1.26 (-1.94 to -0.78) | -0.87 (-1.40 to -0.32) |
| Year 3 (n = 13, 11) | -1.75 (-1.96 to -0.94) | -1.29 (-2.36 to -0.14) |
Fat mass, a measurement of body composition, was assessed by DEXA scan.
| kg | Somatropin- Up To Year 3 (Juvenile Idiopathic Arthritis) | Somatropin- Up To Year 3 (Nephrotic Syndrome) |
|---|---|---|
| Baseline (n = 15, 15) | 5.47 (4.04 to 11.34) | 13.62 (9.51 to 18.05) |
| Year 1 (n = 15, 13) | 4.81 (2.64 to 10.21) | 10.99 (7.22 to 18.97) |
| Year 2 (n = 14, 12) | 6.97 (3.12 to 11.48) | 16.70 (5.99 to 20.59) |
| Year 3 (n = 14, 11) | 6.90 (4.94 to 11.33) | 15.19 (10.28 to 22.87) |
Fat mass, a measurement of body composition, was assessed by DEXA scan. Annual percent change: (Fat mass at current year minus fat mass at previous year) divided by fat mass at previous year, multiplied by 100.
| percent change | Somatropin- Up To Year 3 (Juvenile Idiopathic Arthritis) | Somatropin- Up To Year 3 (Nephrotic Syndrome) |
|---|---|---|
| Annual Change at Year 1 (n = 15, 13) | -11.21 (-24.18 to 27.46) | -3.71 (-19.44 to 15.73) |
| Annual Change at Year 2 (n = 14, 11) | 29.52 (4.97 to 34.56) | -1.05 (-20.82 to 79.15) |
| Annual Change at Year 3 (n = 13, 9) | 26.61 (-4.54 to 52.90) | 19.37 (10.60 to 40.12) |
Fat mass, a measurement of body composition, was assessed by DEXA scan. Percent change: (Fat mass at Year 3 minus fat mass at baseline) divided by fat mass at baseline, multiplied by 100.
| percent change | Somatropin- Up To Year 3 (Juvenile Idiopathic Arthritis) | Somatropin- Up To Year 3 (Nephrotic Syndrome) |
|---|---|---|
| Percent Change From Baseline in Fat Mass at Year 3 | 19.46 (3.83 to 73.79) | 37.56 (8.18 to 44.15) |
Fat mass, a measurement of body composition, was assessed by DEXA scan.
| percentage of total weight | Somatropin- Up To Year 3 (Juvenile Idiopathic Arthritis) | Somatropin- Up To Year 3 (Nephrotic Syndrome) |
|---|---|---|
| Baseline (n = 15, 15) | 25.0 (13.7 to 35.8) | 33.8 (29.5 to 37.2) |
| Year 1 (n = 15, 13) | 17.4 (12.3 to 31.4) | 30.0 (21.9 to 34.7) |
| Year 2 (n = 14, 12) | 21.1 (14.2 to 32.4) | 27.1 (15.0 to 36.2) |
| Year 3 (n = 14, 11) | 21.3 (17.1 to 28.6) | 26.4 (19.1 to 37.6) |
Fat mass was assessed by DEXA scan. Fat mass SDS/CA was obtained by measuring fat mass, subtracting chronological age- and gender-appropriate mean fat mass and dividing the result by standard deviation of that mean (as obtained from chronological age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.
| SDS | Somatropin- Up To Year 3 (Juvenile Idiopathic Arthritis) | Somatropin- Up To Year 3 (Nephrotic Syndrome) |
|---|---|---|
| Baseline (n = 15, 15) | 1.51 (0.50 to 2.22) | 2.20 (1.95 to 2.39) |
| Year 1 (n = 15, 13) | 0.80 (-0.33 to 1.64) | 1.98 (0.88 to 2.23) |
| Year 2 (n = 14, 12) | 0.86 (-0.15 to 1.66) | 1.79 (0.55 to 2.33) |
| Year 3 (n = 13, 11) | 1.27 (0.25 to 1.55) | 1.74 (0.90 to 2.41) |
BMAD (LS) was assessed by DEXA scan.
| gram per cubic centimeter (g/cm^3) | Somatropin- Up To Year 3 (Juvenile Idiopathic Arthritis) | Somatropin- Up To Year 3 (Nephrotic Syndrome) |
|---|---|---|
| Baseline (n = 15, 14) | 0.184 (0.168 to 0.242) | 0.223 (0.211 to 0.241) |
| Year 1 (n = 14, 13) | 0.209 (0.163 to 0.243) | 0.237 (0.201 to 0.244) |
| Year 2 (n = 15, 14) | 0.215 (0.181 to 0.248) | 0.249 (0.217 to 0.266) |
| Year 3 (n = 13, 12) | 0.239 (0.205 to 0.254) | 0.242 (0.223 to 0.266) |
BMAD (LS) was assessed by DEXA scan. BMAD (LS) (SDS/CA) was obtained by measuring the BMAD (LS), subtracting chronological age- and gender-appropriate mean BMAD (LS) and dividing the result by standard deviation of that mean (as obtained from chronological age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.
| SDS | Somatropin- Up To Year 3 (Juvenile Idiopathic Arthritis) | Somatropin- Up To Year 3 (Nephrotic Syndrome) |
|---|---|---|
| Baseline (n = 15, 14) | -3.21 (-4.02 to -1.26) | -1.53 (-1.94 to -1.35) |
| Year 1 (n = 14, 13) | -2.66 (-3.70 to -1.07) | -1.51 (-2.32 to -0.95) |
| Year 2 (n = 15, 14) | -2.55 (-3.74 to -0.95) | -1.42 (-1.86 to -0.72) |
| Year 3 (n 12, 12) | -1.77 (-2.43 to -1.21) | -1.63 (-2.43 to -0.74) |
BMAD (LS) was assessed by DEXA scan. BMAD (LS) (SDS/Tanner Puberty Stage) was obtained by measuring BMAD (LS), subtracting Tanner puberty stage- and gender-appropriate mean BMAD (LS) and dividing the result by standard deviation of that mean (as obtained from Tanner puberty stage- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.
| SDS | Somatropin- Up To Year 3 (Juvenile Idiopathic Arthritis) | Somatropin- Up To Year 3 (Nephrotic Syndrome) |
|---|---|---|
| Baseline (n = 8, 8) | -4.27 (-5.47 to -2.38) | -3.09 (-3.36 to -2.31) |
| Year 1 (n = 10, 7) | -3.70 (-4.80 to -2.48) | -3.23 (-4.64 to -1.74) |
| Year 2 (n = 10, 9) | -4.11 (-4.36 to -1.72) | -2.60 (-3.04 to -2.17) |
| Year 3 (n = 10, 8) | -3.04 (-4.06 to -2.27) | -2.96 (-3.37 to -2.76) |
BMD (TB) was assessed by DEXA scan.
| gram per square centimeter (g/cm^2) | Somatropin- Up To Year 3 (Juvenile Idiopathic Arthritis) | Somatropin- Up To Year 3 (Nephrotic Syndrome) |
|---|---|---|
| Baseline (n = 15, 15) | 0.78 (0.76 to 0.86) | 0.90 (0.81 to 1.00) |
| Year 1 (n = 15, 14) | 0.80 (0.76 to 0.87) | 0.92 (0.85 to 1.02) |
| Year 2 (n = 14, 11) | 0.81 (0.77 to 0.89) | 0.96 (0.86 to 1.09) |
| Year 3 (n = 13, 11) | 0.84 (0.80 to 0.91) | 0.99 (0.89 to 1.08) |
BMD (LS) was assessed by DEXA scan.
| g/cm^2 | Somatropin- Up To Year 3 (Juvenile Idiopathic Arthritis) | Somatropin- Up To Year 3 (Nephrotic Syndrome) |
|---|---|---|
| Baseline (n = 15, 15) | 0.55 (0.47 to 0.64) | 0.72 (0.67 to 0.85) |
| Year 1 (n = 14, 14) | 0.61 (0.48 to 0.74) | 0.76 (0.66 to 0.91) |
| Year 2 (n = 15, 14) | 0.64 (0.56 to 0.84) | 0.85 (0.77 to 1.04) |
| Year 3 (n = 13, 12) | 0.74 (0.60 to 0.85) | 0.93 (0.79 to 1.07) |
DEXA scan of BMC was used to evaluate potential bone effects of treatment. BMC is an estimate of the amount of mineral (such as calcium) in the bone.
| gram | Somatropin- Up To Year 3 (Juvenile Idiopathic Arthritis) | Somatropin- Up To Year 3 (Nephrotic Syndrome) |
|---|---|---|
| Baseline (n = 15, 15) | 636.36 (498.47 to 939.71) | 1233.58 (772.41 to 1650.08) |
| Year 1 (n = 15, 14) | 775.46 (578.97 to 1119.60) | 1576.15 (939.71 to 1739.38) |
| Year 2 (n = 14, 11) | 855.70 (690.07 to 1059.67) | 2003.49 (1070.42 to 2243.61) |
| Year 3 (n = 13, 11) | 1112.78 (807.30 to 1176.70) | 1997.74 (1296.00 to 2195.17) |
BMC is an estimate of the amount of mineral (such as calcium) in the bone. Annual percent change: (BMC \[TB\] at current year minus BMC \[TB\] at previous year) divided by BMC \[TB\] at previous year, multiplied by 100.
| percent change | Somatropin- Up To Year 3 (Juvenile Idiopathic Arthritis) | Somatropin- Up To Year 3 (Nephrotic Syndrome) |
|---|---|---|
| Year 1 (n = 15, 14) | 12.51 (7.66 to 21.86) | 20.16 (11.74 to 23.05) |
| Year 2 (n = 14, 11) | 17.47 (12.20 to 19.93) | 13.91 (10.63 to 18.93) |
| Year 3 (n = 12, 9) | 12.03 (4.50 to 14.54) | 7.39 (7.29 to 13.30) |
BMC is an estimate of the amount of mineral (such as calcium) in the bone. Percent change: (BMC \[TB\] at Year 3 minus BMC \[TB\] at baseline) divided by BMC \[TB\] at baseline, multiplied by 100.
| percent change | Somatropin- Up To Year 3 (Juvenile Idiopathic Arthritis) | Somatropin- Up To Year 3 (Nephrotic Syndrome) |
|---|---|---|
| Percent Change From Baseline in Bone Mineral Content of Total Body (BMC [TB]) at Year 3 | 46.63 (24.94 to 73.91) | 60.56 (36.49 to 67.79) |
BMC (TB) was measured by DEXA scan. BMC (TB) (SDS/CA) was obtained by measuring BMC (TB), subtracting the chronological age- and gender-appropriate mean BMC (TB) and dividing the result by standard deviation of that mean (as obtained from chronological age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.
| SDS | Somatropin- Up To Year 3 (Juvenile Idiopathic Arthritis) | Somatropin- Up To Year 3 (Nephrotic Syndrome) |
|---|---|---|
| Baseline (n = 15, 15) | -1.95 (-2.60 to -1.03) | -0.42 (-1.23 to 0.19) |
| Year 1 (n = 15, 14) | -1.85 (-2.43 to -0.73) | -0.19 (-1.13 to 0.37) |
| Year 2 (n = 14, 11) | -1.66 (-2.27 to -1.14) | -0.37 (-1.24 to 0.43) |
| Year 3 (n = 12, 11) | -1.65 (-2.22 to -0.35) | -0.09 (-0.72 to 0.60) |
BMC (TB) was measured by DEXA scan. BMC (TB) (SDS/Tanner Puberty Stage) was obtained by measuring BMC (TB), subtracting the Tanner puberty stage- and gender-appropriate mean BMC (TB) and dividing the result by standard deviation of that mean (as obtained from Tanner puberty stage- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.
| SDS | Somatropin- Up To Year 3 (Juvenile Idiopathic Arthritis) | Somatropin- Up To Year 3 (Nephrotic Syndrome) |
|---|---|---|
| Baseline (n = 8, 8) | -2.19 (-2.47 to -0.96) | 1.41 (-0.39 to 2.46) |
| Year 1 (n = 10, 8) | -1.56 (-2.24 to -0.92) | -0.52 (-1.53 to 1.65) |
| Year 2 (n = 9, 7) | -2.38 (-2.72 to -1.14) | -0.47 (-1.53 to 0.37) |
| Year 3 (n = 9, 7) | -2.38 (-2.56 to -1.28) | -0.17 (-1.22 to 0.83) |
Growth velocity measures the annual rate of increase in height.
| cm/year | Somatropin- Up To Year 3 (Juvenile Idiopathic Arthritis) | Somatropin- Up To Year 3 (Nephrotic Syndrome) |
|---|---|---|
| Baseline (n = 11, 14) | 2.9 (1.1 to 4.8) | 3.8 (2.7 to 4.4) |
| Year 1 (n = 14, 15) | 6.5 (3.5 to 8.6) | 8.3 (5.4 to 8.7) |
| Year 2 (n = 14, 15) | 5.3 (1.8 to 6.9) | 7.0 (4.1 to 9.2) |
| Year 3 (n = 14, 14) | 4.5 (1.9 to 6.8) | 5.9 (2.3 to 7.2) |
GV measures the annual rate of increase in height. GV (SDS/CA) was obtained by measuring GV, subtracting the chronological age- and gender-appropriate mean GV and dividing the result by standard deviation of that mean (as obtained from chronological age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.
| SDS | Somatropin- Up To Year 3 (Juvenile Idiopathic Arthritis) | Somatropin- Up To Year 3 (Nephrotic Syndrome) |
|---|---|---|
| Baseline (n = 10, 14) | -1.7 (-2.8 to -1.3) | -2.2 (-2.9 to -1.3) |
| Year 1 (n = 14, 15) | 1.0 (-1.5 to 3.9) | 1.3 (-0.7 to 1.9) |
| Year 2 (n = 14, 15) | 0.1 (-1.9 to 3.7) | 2.9 (1.4 to 4.2) |
| Year 3 (n = 14, 14) | 0.4 (-0.5 to 2.1) | 2.9 (-0.1 to 5.7) |
GV measures the annual rate of increase in height. GV (SDS/BA) was obtained by measuring GV, subtracting the bone age- and gender-appropriate mean GV and dividing the result by standard deviation of that mean (as obtained from bone age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.
| SDS | Somatropin- Up To Year 3 (Juvenile Idiopathic Arthritis) | Somatropin- Up To Year 3 (Nephrotic Syndrome) |
|---|---|---|
| Baseline (n = 9, 14) | -2.8 (-3.9 to -1.7) | -2.1 (-2.4 to -1.1) |
| Year 1 (n = 13, 15) | 0.8 (-0.9 to 2.9) | 0.6 (-0.6 to 2.4) |
| Year 2 (n = 14, 13) | -0.3 (-3.9 to 1.1) | 1.4 (-0.6 to 2.0) |
| Year 3 (n = 14, 14) | -0.9 (-2.2 to 0.9) | 0.1 (-1.7 to 3.4) |
| nanogram per milliliter (ng/mL) | Somatropin- Up To Year 3 (Juvenile Idiopathic Arthritis) | Somatropin- Up To Year 3 (Nephrotic Syndrome) |
|---|---|---|
| Baseline (n = 15, 12) | 157.0 (61.0 to 345.0) | 344.5 (191.0 to 719.0) |
| Year 1 (n = 15, 15) | 400.0 (154.0 to 1370) | 952.0 (424.0 to 1658.0) |
| Year 2 (n = 15, 14) | 388.0 (188.0 to 1338.0) | 880.0 (311.0 to 1718.0) |
| Year 3 (n = 15, 14) | 405.0 (239.0 to 1160.0) | 657.0 (323.0 to 1298.0) |
| milligram per deciliter (mg/dL) | Somatropin- After Year 3 |
|---|---|
| Year 3.5 (n = 8) | 0.05 (0.04 to 0.09) |
| Year 4 (n = 19) | 0.06 (0.03 to 0.10) |
| Year 4.5 (n = 16) | 0.06 (0.02 to 0.14) |
| Year 5 (n = 17) | 0.05 (0.02 to 0.09) |
| Year 5.5 (n = 11) | 0.06 (0.02 to 0.09) |
| Year 6 (n = 14) | 0.05 (0.02 to 0.08) |
| Year 6.5 (n = 8) | 0.07 (0.02 to 0.09) |
| Year 7 (n = 8) | 0.06 (0.02 to 0.07) |
| Year 7.5 (n = 4) | 0.05 (0.03 to 0.07) |
| Year 8 (n = 6) | 0.06 (0.03 to 0.07) |
| Year 8.5 (n = 2) | 0.08 (0.07 to 0.08) |
| Year 9 (n = 2) | 0.06 (0.06 to 0.07) |
| Year 9.5 (n = 1) | 0.07 (0.07 to 0.07) |
| Year 10 (n = 1) | 0.05 (0.05 to 0.05) |
| 0.5 years after somatropin discontinuation (n = 2) | 0.03 (0.03 to 0.04) |
| 1 year after somatropin discontinuation (n = 2) | 0.03 (0.02 to 0.05) |
| Final height (n = 3) | 0.06 (0.05 to 0.07) |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Somatropin- Up To Year 3 (Juvenile Idiopathic Arthritis) | — | 13/15 (86.7%) | 13/15 (86.7%) |
| Somatropin- Up To Year 3 (Nephrotic Syndrome) | — | 14/15 (93.3%) | 14/15 (93.3%) |
| Somatropin- After Year 3 | — | 19/21 (90.5%) | 21/21 (100%) |
| Event | Somatropin- Up To Year 3 (Juvenile Idiopathic Arthritis) | Somatropin- Up To Year 3 (Nephrotic Syndrome) | Somatropin- After Year 3 |
|---|---|---|---|
| Nephrotic syndromeRenal and urinary disorders | 0/15 | 9/15 | 4/21 |
| Juvenile arthritisMusculoskeletal and connective tissue disorders | 2/15 | 0/15 | 6/21 |
| Condition aggravatedGeneral disorders | 3/15 | 2/15 | 0/21 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 3/15 | 0/15 | 1/21 |
| Abdominal painGastrointestinal disorders | 2/15 | 1/15 | 4/21 |
| Hip arthroplastySurgical and medical procedures | 0/15 | 0/15 | 3/21 |
| Diabetes mellitusMetabolism and nutrition disorders | 1/15 | 2/15 | 2/21 |
| GastroenteritisInfections and infestations | 2/15 | 1/15 | 2/21 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/15 | 2/15 | 0/21 |
| Biopsy kidneyInvestigations | 0/15 | 1/15 | 2/21 |
| Event | Somatropin- Up To Year 3 (Juvenile Idiopathic Arthritis) | Somatropin- Up To Year 3 (Nephrotic Syndrome) | Somatropin- After Year 3 |
|---|---|---|---|
| Nephrotic syndromeRenal and urinary disorders | 0/15 | 11/15 | 7/21 |
| ProteinuriaRenal and urinary disorders | 0/15 | 6/15 | 3/21 |
| Red blood cell sedimentation rate increasedInvestigations | 5/15 | 0/15 | 4/21 |
| Joint effusionMusculoskeletal and connective tissue disorders | 4/15 | 0/15 | 4/21 |
| Juvenile arthritisMusculoskeletal and connective tissue disorders | 3/15 | 0/15 | 5/21 |
| Ear infectionInfections and infestations | 0/15 | 3/15 | 2/21 |
| NasopharyngitisInfections and infestations | 0/15 | 3/15 | 2/21 |
| RhinitisInfections and infestations | 0/15 | 3/15 | 2/21 |
| Insulin-like growth factor increasedInvestigations | 0/15 | 3/15 | 3/21 |
| HypertriglyceridaemiaMetabolism and nutrition disorders | 0/15 | 3/15 | 1/21 |
| Age Continuous(years) | Somatropin- Up To Year 3 (Juvenile Idiopathic Arthritis) | Somatropin- Up To Year 3 (Nephrotic Syndrome) | Total |
|---|---|---|---|
| Mean | 11.14 ± 3.32 | 11.96 ± 3.80 | 11.55 ± 3.53 |
| Sex: Female, Male(Participants) | Somatropin- Up To Year 3 (Juvenile Idiopathic Arthritis) | Somatropin- Up To Year 3 (Nephrotic Syndrome) | Total |
|---|---|---|---|
| Female | 9 | 2 | 11 |
| Male | 6 | 13 | 19 |
The record gives a start of Sep 2000, a primary completion of Sep 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2012, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Human Growth Hormone